Tirdzniecība Altimmune, Inc. - ALT CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Starpība | 0.07 | ||||||||
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
Nakts laika nodeva | 21:00 (UTC) | ||||||||
Min. tirgotais daudzums | 1 | ||||||||
Valūta | USD | ||||||||
Drošības rezerve | 20% | ||||||||
Fondu birža | United States of America | ||||||||
Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Altimmune Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Iepriekš. aizvērt* | 4.11 |
Atvērt* | 4.07 |
Izmaiņas par 1 gadu* | -17.28% |
Dienas Diapazons* | 4.07 - 4.23 |
52 ned Diapazons | 3.82-23.49 |
Vidējais apjoms (10 dienas) | 1.43M |
Vidējais apjoms (3 mēneši) | 45.19M |
Tirgus Kapitalizācija | 199.14M |
Cenas/Peļņas Attiecība | -100.00K |
Izvietotās Akcijas | 49.29M |
Ieņēmumi | -79.00K |
EPS | -1.76 |
Dividende (Ienesīgums %) | N/A |
Beta | -0.07 |
Nākamās Peļņas Datums | Aug 9, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
---|---|---|---|---|---|---|
Jun 1, 2023 | 4.11 | 0.15 | 3.79% | 3.96 | 4.21 | 3.90 |
May 31, 2023 | 4.02 | 0.08 | 2.03% | 3.94 | 4.13 | 3.93 |
May 30, 2023 | 3.97 | -0.07 | -1.73% | 4.04 | 4.14 | 3.96 |
May 26, 2023 | 4.06 | -0.12 | -2.87% | 4.18 | 4.22 | 4.00 |
May 25, 2023 | 4.21 | 0.05 | 1.20% | 4.16 | 4.29 | 4.14 |
May 24, 2023 | 4.27 | -0.09 | -2.06% | 4.36 | 4.40 | 4.18 |
May 23, 2023 | 4.39 | 0.03 | 0.69% | 4.36 | 4.77 | 4.32 |
May 22, 2023 | 4.44 | -0.01 | -0.22% | 4.45 | 4.58 | 4.38 |
May 19, 2023 | 4.43 | 0.05 | 1.14% | 4.38 | 4.60 | 4.38 |
May 18, 2023 | 4.42 | -0.07 | -1.56% | 4.49 | 4.55 | 4.25 |
May 17, 2023 | 4.57 | -0.02 | -0.44% | 4.59 | 4.68 | 4.50 |
May 16, 2023 | 4.62 | -0.17 | -3.55% | 4.79 | 4.86 | 4.60 |
May 15, 2023 | 4.80 | -0.28 | -5.51% | 5.08 | 5.30 | 4.76 |
May 12, 2023 | 5.05 | -0.28 | -5.25% | 5.33 | 5.52 | 4.96 |
May 11, 2023 | 5.31 | 0.37 | 7.49% | 4.94 | 5.41 | 4.84 |
May 10, 2023 | 4.92 | 0.03 | 0.61% | 4.89 | 5.06 | 4.73 |
May 9, 2023 | 4.90 | 0.08 | 1.66% | 4.82 | 5.02 | 4.73 |
May 8, 2023 | 4.89 | 0.01 | 0.20% | 4.88 | 4.94 | 4.74 |
May 5, 2023 | 4.89 | 0.02 | 0.41% | 4.87 | 5.09 | 4.85 |
May 4, 2023 | 4.89 | 0.01 | 0.20% | 4.88 | 4.98 | 4.64 |
Altimmune, Inc. Events
Laiks (UTC) (UTC) | Valsts | Notikums |
---|---|---|
Wednesday, August 9, 2023 | ||
Laiks (UTC) (UTC) 12:30 | Valsts US
| Notikums Q2 2023 Altimmune Inc Earnings Release Q2 2023 Altimmune Inc Earnings ReleaseForecast -Previous - |
Friday, September 29, 2023 | ||
Laiks (UTC) (UTC) 12:30 | Valsts US
| Notikums Altimmune Inc Annual Shareholders Meeting Altimmune Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, November 8, 2023 | ||
Laiks (UTC) (UTC) 13:30 | Valsts US
| Notikums Q3 2023 Altimmune Inc Earnings Release Q3 2023 Altimmune Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kopējie ienākumi | -0.068 | 4.41036 | 8.18503 | 5.8014 | 10.3312 |
Ienākumi | -0.068 | 4.41036 | 8.18503 | 5.8014 | 10.3312 |
Kopējie Darbības Izdevumi | 87.672 | 101.324 | 62.9838 | 27.2663 | 53.1656 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 17.134 | 15.4133 | 13.2094 | 8.50078 | 9.76558 |
Pētniecība un Attīstība | 70.538 | 74.5212 | 49.7275 | 17.618 | 18.3757 |
Neparedzēti Izdevumi (Ienākumi) | 0 | 11.37 | 0 | 1 | 24.9407 |
Darbības Izdevumi | -87.74 | -96.914 | -54.7987 | -21.4649 | -42.8344 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 2.862 | 0.19708 | 0.31309 | 0.87117 | -2.76442 |
Citi, Neto | -0.032 | -0.37387 | 0.02415 | 0.01514 | 0.27789 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -84.91 | -97.0908 | -54.4615 | -20.5786 | -45.3209 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -84.713 | -97.0908 | -49.0445 | -20.5201 | -39.1712 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -84.713 | -97.0908 | -49.0445 | -20.5201 | -39.1712 |
Neto Ienākumi | -84.713 | -97.0908 | -49.0445 | -20.5201 | -39.1712 |
Total Adjustments to Net Income | 0 | -0.45293 | -3.3078 | ||
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -84.713 | -97.0908 | -49.0445 | -20.9731 | -42.479 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -84.713 | -97.0908 | -49.0445 | -20.9731 | -42.479 |
Atšķaidītie Neto Ienākumi | -84.713 | -97.0908 | -49.0445 | -20.9731 | -42.479 |
Atšķaidītie Ienākumi par Akcijām | 46.9263 | 41.2835 | 25.637 | 13.125 | 2.80238 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -1.80523 | -2.35181 | -1.91303 | -1.59795 | -15.1582 |
Dividends per Share - Common Stock Primary Issue | |||||
Atšķaidītā Normalizētā Peļņa par Akciju | -1.80523 | -2.07639 | -1.91303 | -1.54843 | -9.37328 |
Depreciation / Amortization | 0.01992 | 0.04681 | 0.1475 | 0.08365 | |
Ārkārtas Posteņi Kopā | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kopējie ienākumi | 0.021 | -0.068 | 0.002 | 0.008 | 0.032 |
Ienākumi | 0.021 | -0.068 | 0.002 | 0.008 | 0.032 |
Kopējie Darbības Izdevumi | 21.78 | 87.672 | 24.754 | 20.403 | 19.531 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 4.531 | 17.134 | 4.492 | 4.41 | 4.427 |
Pētniecība un Attīstība | 17.249 | 70.538 | 20.262 | 15.993 | 15.104 |
Darbības Izdevumi | -21.759 | -87.74 | -24.752 | -20.395 | -19.499 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 1.666 | 2.862 | 0.989 | 0.263 | -0.041 |
Citi, Neto | 0.019 | -0.032 | 0.05 | 0.025 | 0.11 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -20.074 | -84.91 | -23.713 | -20.107 | -19.43 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
Neto Ienākumi | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
Atšķaidītie Neto Ienākumi | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
Atšķaidītie Ienākumi par Akcijām | 50.1257 | 46.9263 | 49.2865 | 47.5026 | 43.9695 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.40047 | -1.80523 | -0.47713 | -0.42328 | -0.4419 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Atšķaidītā Normalizētā Peļņa par Akciju | -0.40047 | -1.80523 | -0.47713 | -0.42328 | -0.4419 |
Neparedzēti Izdevumi (Ienākumi) | 0 | 0 | 0 |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 192.813 | 204.126 | 230.257 | 39.3947 | 39.3721 |
Nauda un Īstermiņa Ieguldījumi | 184.88 | 190.301 | 215.923 | 37.2401 | 33.7187 |
Nauda un Ekvivalenti | 111.097 | 190.301 | 115.918 | 8.96269 | 33.7187 |
Debitoru Parādu Kopsumma, Neto | 2.541 | 5.83848 | 12.373 | 1.65028 | 4.47091 |
Accounts Receivable - Trade, Net | 0.173 | 0.42884 | 4.6102 | 1.02118 | 3.46194 |
Prepaid Expenses | 5.358 | 7.95269 | 1.92668 | 0.47023 | 0.54809 |
Other Current Assets, Total | 0.034 | 0.03417 | 0.03417 | 0.03417 | 0.63442 |
Total Assets | 206.928 | 218.865 | 245.115 | 54.058 | 54.7505 |
Property/Plant/Equipment, Total - Net | 1.677 | 2.24596 | 1.96075 | 1.80253 | 1.3428 |
Property/Plant/Equipment, Total - Gross | 3.175 | 4.29284 | 3.55956 | 3.1501 | 2.45055 |
Accumulated Depreciation, Total | -1.498 | -2.04688 | -1.59881 | -1.34757 | -1.10775 |
Goodwill, Net | |||||
Intangibles, Net | 12.419 | 12.419 | 12.8238 | 12.7322 | 13.8519 |
Other Long Term Assets, Total | 0.019 | 0.0738 | 0.07341 | 0.12855 | 0.18368 |
Total Current Liabilities | 17.054 | 18.2759 | 12.0204 | 3.923 | 4.52741 |
Accounts Payable | 4.804 | 2.03449 | 0.61229 | 0.01823 | 0.37286 |
Accrued Expenses | 11.081 | 10.1514 | 11.3884 | 3.8432 | 4.0632 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.169 | 6.09 | 0.01975 | 0.06156 | 0.01975 |
Total Liabilities | 21.635 | 19.7301 | 19.2389 | 8.53787 | 6.43798 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0.50117 |
Long Term Debt | 0 | 0.50117 | |||
Deferred Income Tax | 0.0585 | ||||
Other Liabilities, Total | 4.581 | 1.4542 | 7.21844 | 4.61488 | 1.3509 |
Total Equity | 185.293 | 199.135 | 225.876 | 45.5201 | 48.3126 |
Redeemable Preferred Stock | 0 | ||||
Common Stock | 0.005 | 0.00409 | 0.0037 | 0.00151 | 0.00088 |
Additional Paid-In Capital | 568.399 | 497.342 | 417.338 | 187.915 | 170.208 |
Retained Earnings (Accumulated Deficit) | -377.884 | -293.171 | -186.421 | -137.376 | -116.856 |
Other Equity, Total | -5.227 | -5.04016 | -5.04452 | -5.02016 | -5.04016 |
Total Liabilities & Shareholders’ Equity | 206.928 | 218.865 | 245.115 | 54.058 | 54.7505 |
Total Common Shares Outstanding | 49.1998 | 40.9938 | 37.1429 | 15.3122 | 9.07824 |
Current Port. of LT Debt/Capital Leases | 0 | 0.0716 | |||
Īstermiņa Ieguldījumi | 73.783 | 0 | 100.006 | 28.2774 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 173.111 | 192.813 | 211.004 | 195.504 | 191.093 |
Nauda un Īstermiņa Ieguldījumi | 165.729 | 184.88 | 201.827 | 184.756 | 179.947 |
Nauda un Ekvivalenti | 104.69 | 111.097 | 127.465 | 135.858 | 179.947 |
Īstermiņa Ieguldījumi | 61.039 | 73.783 | 74.362 | 48.898 | |
Debitoru Parādu Kopsumma, Neto | 3.37 | 2.541 | 4.353 | 6.095 | 6.073 |
Accounts Receivable - Trade, Net | 0.252 | 0.173 | 0.633 | 0.195 | 0.193 |
Prepaid Expenses | 3.978 | 5.358 | 4.79 | 4.619 | 5.039 |
Other Current Assets, Total | 0.034 | 0.034 | 0.034 | 0.034 | 0.034 |
Total Assets | 187.083 | 206.928 | 225.277 | 209.906 | 205.66 |
Property/Plant/Equipment, Total - Net | 1.548 | 1.677 | 1.821 | 1.937 | 2.087 |
Property/Plant/Equipment, Total - Gross | 3.175 | 3.212 | |||
Accumulated Depreciation, Total | -1.498 | -1.125 | |||
Intangibles, Net | 12.419 | 12.419 | 12.419 | 12.419 | 12.419 |
Other Long Term Assets, Total | 0.005 | 0.019 | 0.033 | 0.046 | 0.061 |
Total Current Liabilities | 14.951 | 17.054 | 15.742 | 13.845 | 19.124 |
Accounts Payable | 5.238 | 4.804 | 1.419 | 2.872 | 2.205 |
Accrued Expenses | 8.544 | 11.081 | 13.154 | 10.973 | 12.609 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.169 | 1.169 | 1.169 | 0 | 4.31 |
Total Liabilities | 19.351 | 21.635 | 20.248 | 15.371 | 20.792 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 4.4 | 4.581 | 4.506 | 1.526 | 1.668 |
Total Equity | 167.732 | 185.293 | 205.029 | 194.535 | 184.868 |
Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.004 |
Additional Paid-In Capital | 570.786 | 568.399 | 566.551 | 532.398 | 502.505 |
Retained Earnings (Accumulated Deficit) | -397.958 | -377.884 | -356.224 | -332.708 | -312.601 |
Other Equity, Total | -5.101 | -5.227 | -5.303 | -5.16 | -5.04 |
Total Liabilities & Shareholders’ Equity | 187.083 | 206.928 | 225.277 | 209.906 | 205.66 |
Total Common Shares Outstanding | 49.2867 | 49.1998 | 49.1616 | 46.3721 | 43.2199 |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Neto ienākumi/Sākuma Līnija | -84.713 | -97.0908 | -49.0445 | -20.5201 | -39.1712 |
Nauda no Darbības | -62.586 | -78.2379 | -34.3058 | -9.602 | -9.38891 |
Nauda no Darbības | 0.5513 | 0.42888 | 0.23982 | 0.21872 | |
Amortization | 0.1475 | 0.08365 | |||
Bezskaidras Naudas Preces | 8.016 | 18.5521 | 18.8219 | 8.76996 | 28.6495 |
Cash Taxes Paid | 0 | 0.00179 | 0 | 0.05721 | |
Izmaiņas Apgrozāmajā Kapitālā | 14.111 | -0.25053 | -4.51216 | 1.81936 | 6.98019 |
Nauda no Ieguldījumu Darbībām | -73.399 | 87.5231 | -72.2258 | -28.2864 | -1.00114 |
Kapitālie Izdevumi | -0.126 | -12.3117 | -0.34242 | -0.029 | -1.01563 |
Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -73.273 | 99.8348 | -71.8834 | -28.2574 | 0.01449 |
Nauda no Darbībām ar Finansēšanu | 56.781 | 65.0978 | 213.487 | 12.5321 | 32.4899 |
Naudas Plūsma Finansēšanas Posteņos | 0 | -0.11852 | 0 | ||
Akciju Izsniegšana (Atkāpšanās), Neto | 56.781 | 65.2163 | 213.487 | 12.8241 | 34.0396 |
Parādu Izsniegšana (Atkāpšanās), Neto | 0 | 0 | -0.292 | -1.5497 | |
Ārvalstu Valūtas Ietekme | -0.05037 | ||||
Neto Izmaiņas Naudā | -79.204 | 74.383 | 106.955 | -25.3563 | 22.0495 |
Deferred Taxes | -0.0585 | -6.14979 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -20.074 | -84.713 | -63.053 | -39.537 | -19.43 |
Cash From Operating Activities | -19.407 | -62.586 | -45.28 | -30.23 | -13.526 |
Cash From Operating Activities | 0.031 | 0.172 | 0.119 | ||
Non-Cash Items | 2.301 | 8.016 | 6.112 | 4.033 | 0.143 |
Changes in Working Capital | -1.634 | 14.111 | 11.63 | 5.102 | 5.642 |
Cash From Investing Activities | 13.302 | -73.399 | -74.38 | -48.977 | -0.009 |
Capital Expenditures | -0.051 | -0.126 | -0.088 | -0.028 | -0.009 |
Other Investing Cash Flow Items, Total | 13.353 | -73.273 | -74.292 | -48.949 | 0 |
Cash From Financing Activities | -0.302 | 56.781 | 56.824 | 24.764 | 3.181 |
Financing Cash Flow Items | -0.013 | 0 | 0 | -0.036 | -0.119 |
Issuance (Retirement) of Stock, Net | -0.289 | 56.781 | 56.824 | 24.8 | 3.3 |
Net Change in Cash | -6.407 | -79.204 | -62.836 | -54.443 | -10.354 |
Cash Taxes Paid | |||||
Issuance (Retirement) of Debt, Net |
Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
---|---|---|---|---|---|---|
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 10.0609 | 4959254 | -955334 | 2023-03-31 | LOW |
Laurion Capital Management LP | Hedge Fund | 7.1032 | 3501330 | 2750030 | 2023-03-31 | HIGH |
Nuveen LLC | Pension Fund | 6.63 | 3268061 | 2098 | 2023-03-31 | LOW |
Tang Capital Management, LLC | Hedge Fund | 5.579 | 2750000 | 49550 | 2023-03-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.1227 | 2525113 | 5301 | 2023-03-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 4.1477 | 2044485 | 885024 | 2023-03-31 | HIGH |
Two Sigma Investments, LP | Hedge Fund | 4.1162 | 2028982 | 327385 | 2023-03-31 | HIGH |
Marshall Wace LLP | Investment Advisor/Hedge Fund | 3.2401 | 1597130 | 357336 | 2023-03-31 | HIGH |
Ardsley Advisory Partners LP | Hedge Fund | 2.9361 | 1447250 | 742500 | 2023-03-31 | MED |
Avidity Partners Management LP | Hedge Fund | 2.6682 | 1315200 | -2674800 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6611 | 1311736 | 9245 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 2.1682 | 1068745 | 924007 | 2023-03-31 | HIGH |
Goldman Sachs & Company, Inc. | Research Firm | 1.6723 | 824323 | 86346 | 2023-03-31 | MED |
Susquehanna International Group, LLP | Investment Advisor | 1.6163 | 796722 | 444649 | 2023-03-31 | MED |
Qube Research & Technologies Ltd | Hedge Fund | 1.385 | 682680 | 670035 | 2023-03-31 | HIGH |
Ikarian Capital LLC | Hedge Fund | 1.3741 | 677300 | 403868 | 2023-03-31 | HIGH |
BofA Global Research (US) | Research Firm | 1.3108 | 646146 | 123630 | 2023-03-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.1493 | 566501 | 388636 | 2023-03-31 | LOW |
Tri Locum Partners LP | Hedge Fund | 1.0728 | 528814 | 203120 | 2023-03-31 | LOW |
Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 1.048 | 516563 | -82324 | 2023-03-31 | MED |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group535K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$113M+
Ikmēneša ieguldījumu apjoms
$64M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Altimmune, Inc. Company profile
Par Altimmune, Inc.
Altimmune, Inc. ir klīniskās stadijas biofarmācijas uzņēmums, kas nodarbojas ar aptaukošanās un aknu slimību ārstēšanas līdzekļu izstrādi. Uzņēmuma vadošais kandidātprodukts - pemvidutids (ierosinātais INN, agrāk pazīstams kā ALT-801) - ir GLP-1/glukāgona duālo receptoru agonists, kas tiek izstrādāts aptaukošanās un nealkoholiskā steatohepatīta (NASH) ārstēšanai. Uzņēmums izstrādā arī HepTcell - imunoterapeitisku līdzekli, kas paredzēts hroniska hepatīta B funkcionālai izārstēšanai. Uzņēmums ir uzsācis HepTcell II fāzes klīnisko izpēti un veic pemvidutida II fāzes un I fāzes klīnisko izpēti vairākām indikācijām. Uzņēmums veic HepTcell II fāzes klīnisko pētījumu Amerikas Savienotajās Valstīs, Apvienotajā Karalistē, Kanādā, Vācijā un Spānijā un veic pemvidutida I fāzes klīnisko pētījumu Austrālijā. Uzņēmumam pilnībā piederošie meitasuzņēmumi ir Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC un Altimmune AU Pty, Limited.
Industry: | Bio Therapeutic Drugs |
910 Clopper Rd Ste 201S
GAITHERSBURG
MARYLAND 20878-1361
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 535 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com